<?xml version="1.0" encoding="UTF-8"?>
<document id="29321482">
	<sentence id="s1" text="Epidermal growth factor receptor (EGFR) mutation is prevalently expressed in lung adenocarcinoma cases and acts as one of the major driving oncogenes.">
		<entity id="s1.e1" charOffset="34-38"
			type="GENE" text="EGFR" ontology_id="1956"/>
		<entity id="s1.e2" charOffset="77-96"
			type="HP" text="lung adenocarcinoma" ontology_id="HP_0030078"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="EGFR tyrosine kinase inhibitors (TKIs) have been used in patients with EGFR-mutant as an effective targeted therapy in lung adenocarcinoma, but drug resistance and tumor recurrence inevitably occurs.">
		<entity id="s2.e1" charOffset="0-4"
			type="GENE" text="EGFR" ontology_id="1956"/>
		<entity id="s2.e2" charOffset="119-138"
			type="HP" text="lung adenocarcinoma" ontology_id="HP_0030078"/>
		<entity id="s2.e3" charOffset="164-169"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
		<pair id="s2.p2" e1="s2.e1"
		    e2="s2.e3" pgr="true"/>
	</sentence>
	<sentence id="s3" text="Recently, Yes-associate protein (YAP) has been reported to promote multiple cancer cell properties, such as promoting cell proliferation, epithelial-mesenchymal transition and drug resistance.">
		<entity id="s3.e1" charOffset="10-13"
			type="GENE" text="Yes" ontology_id="7525"/>
		<entity id="s3.e2" charOffset="33-36"
			type="GENE" text="YAP" ontology_id="55249"/>
		<entity id="s3.e3" charOffset="76-82"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p2" e1="s3.e2"
		    e2="s3.e3" pgr="false"/>
	</sentence>
	<sentence id="s4" text="This study investigated the roles of YAP in TKI-resistant lung adenocarcinoma.">
		<entity id="s4.e1" charOffset="37-40"
			type="GENE" text="YAP" ontology_id="55249"/>
		<entity id="s4.e2" charOffset="58-77"
			type="HP" text="lung adenocarcinoma" ontology_id="HP_0030078"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="false"/>
	</sentence>
	<sentence id="s5" text="With reduced YAP expression using shRNA or YAP inhibitors, TKI-resistant cells become TKI-sensitive. reduced xenograft tumor size in nude mice and Moreover, combined EGFR TKI and a YAP inhibitor, statin, prolonged survival among lung cancer patients analyzed by Taiwan National Health Insurance Research database.">
		<entity id="s5.e1" charOffset="13-16"
			type="GENE" text="YAP" ontology_id="55249"/>
		<entity id="s5.e2" charOffset="119-124"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s5.e3" charOffset="133-137"
			type="GENE" text="nude" ontology_id="54820"/>
		<entity id="s5.e4" charOffset="138-142"
			type="GENE" text="mice" ontology_id="23581"/>
		<entity id="s5.e5" charOffset="166-170"
			type="GENE" text="EGFR" ontology_id="1956"/>
		<entity id="s5.e6" charOffset="234-240"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s5.p1" e1="s5.e5"
		    e2="s5.e5" pgr="true"/>
		<pair id="s5.p2" e1="s5.e1"
		    e2="s5.e2" pgr="false"/>
		<pair id="s5.p3" e1="s5.e2"
		    e2="s5.e3" pgr="false"/>
		<pair id="s5.p4" e1="s5.e2"
		    e2="s5.e4" pgr="false"/>
		<pair id="s5.p5" e1="s5.e5"
		    e2="s5.e6" pgr="true"/>
		<pair id="s5.p6" e1="s5.e1"
		    e2="s5.e10" pgr="false"/>
		<pair id="s5.p7" e1="s5.e6"
		    e2="s5.e10" pgr="false"/>
		<pair id="s5.p8" e1="s5.e8"
		    e2="s5.e10" pgr="false"/>
	</sentence>
</document>
